UniQure rises as it seeks equity raise following FDA about-face
BUZZ-UniQure rises as it seeks equity raise following FDA about-face ** U.S.-listed shares of uniQure NV QURE.O up 7.6% to $47.76 on Tues as Dutch drugmaker looks to raise equity on heels of U.S. FDA reversing its earlier position on co's Huntington's disease treatment
** QURE late Mon kicked off $150 mln offering of stock and pre-funded warrants
** Last Weds, co's shares surged ~78% to close at $48.16 after U.S. health regulator said it will accept existing trial data for an accelerated review of AMT-130
** QURE intends to use net proceeds from offering to fund commercialization activities, potential commercial launches and studies of AMT-130, and to develop other product candidates, among other purposes, per the prospectus
** Leerink Partners and Stifel joint bookrunners
** Co has ~63.1 mln shares outstanding
** With the advance, U.S.-listed shares have doubled YTD
** 13 of 15 analysts rate the shares "strong buy" or "buy", 2 "hold"; median PT $60.50, per LSEG
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
Recent news on uniQure
See all newsuniQure tumbles after updated Huntington's disease gene therapy data
UniQure plunges as Huntington's trial data disappoints investors (updated)
uniQure tumbles after updated Huntington's disease gene therapy data
UniQure's Huntington's therapy fails to significantly slow disease progression in trial
uniQure seeks US approval for Huntington's gene therapy after FDA reversal